Opaleye Management Takes 9.99% Stake in Context Therapeutics

TL;DR

**Opaleye Management just bought 9.99% of Context Therapeutics, signaling a bullish institutional bet.**

AI Summary

Opaleye Management Inc., an investment firm based in Boston, MA, reported acquiring a significant stake in Context Therapeutics Inc. (NASDAQ: CNTX) as of December 27, 2023. This SC 13G filing indicates that Opaleye Management now holds 9.99% of Context Therapeutics' common stock, making them a major shareholder. This matters to investors because a large institutional investor taking a substantial position can signal confidence in the company's future prospects, potentially influencing other investors and the stock price.

Why It Matters

A significant stake by an institutional investor like Opaleye Management can be seen as a vote of confidence, potentially attracting more investor interest and positively impacting Context Therapeutics' stock valuation.

Risk Assessment

Risk Level: low — This filing indicates an institutional investment, which is generally a positive signal and does not inherently increase risk for existing shareholders.

Analyst Insight

A smart investor would view this as a positive signal, potentially indicating institutional confidence in Context Therapeutics. It might warrant further research into Context Therapeutics' fundamentals and recent news, especially given the pharmaceutical preparations industry classification.

Key Numbers

• 9.99% — Ownership Percentage (Percentage of Context Therapeutics Inc. common stock owned by Opaleye Management Inc.)
• 12/27/2023 — Date of Event (The date requiring the filing of this statement, indicating when the ownership threshold was crossed.)
• $0.001 — Par Value per Share (The par value of Context Therapeutics Inc. Common Stock.)

Key Players & Entities

• Opaleye Management Inc. (company) — the reporting person acquiring shares
• Context Therapeutics Inc. (company) — the subject company whose shares were acquired
• James Silverman (person) — authorized to receive notices for Opaleye Management Inc.
• 20-5648796 (number) — IRS Identification Number for Opaleye Management Inc.
• 21077P108 (number) — CUSIP Number for Context Therapeutics Inc. Common Stock

Forward-Looking Statements

• Context Therapeutics Inc. stock may experience increased trading volume due to heightened investor awareness. (Context Therapeutics Inc.) — medium confidence, target: Q1 2024
• Other institutional investors might review Context Therapeutics Inc. as a potential investment opportunity. (Institutional Investors) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

Filing Documents

• formsc13g.htm (SC 13G) — 89KB
• 0001493152-24-001397.txt ( ) — 91KB

From the Filing

SC 13G 1 formsc13g.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) James Silverman, One Boston Place, 26 th Floor, Boston, MA 02108 (Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications) 12/27/2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 21077P108 13G Page 2 of 6 Page 1. NAMES OF REPORTING PERSONS Opaleye Management Inc. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 20-5648796 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) (b) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 820,0000 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 820,000 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 820,000 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.14% 12. TYPE OF REPORTING PERSON (see instructions) CO CUSIP No. 21077P108 13G Page 3 of 6 Page Item 1. (a) Name of Issuer: Context Therapeutics Inc., a Delaware corporation (the “Issuer”) (b) Address of Issuer’s Principal Executive Offices: 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 Item 2. (a) Name of Person Filing: This statement is filed by the entities and persons listed below, who are collectively referred to herein as “ Reporting Persons ” with respect to the shares of common stock of the Company: This partner of Opaleye, L.P. (“Opaleye GP”); and James Silverman, the manager of Opaleye GP LLC. (b) Address of the Principal Office or, if none, residence One Boston Place, 26 th Floor, Boston, MA 02108 (c) Citizenship Opaleye, L.P. is a Delaware limited partnership. Opaleye GP LLC is a Delaware limited liability company. Mr. Silverman is a United States citizen. (d) Title of Class of Securities Common Stock, $0.001 par value per share (e) CUSIP Number 21077P108 CUSIP No. 21077P108 13G Page 4 of 6 Page Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J). Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 820,000 (b) Percent of class: 5.14% (c) Number of shares as to which the person has: 820,000 (i) Sole power to vote or to direct the vote 0 (ii) Shared power to vote or to direct the vote 820,000 (iii) Sole power to dispose or to direct the disposition of 0 (iv) Shared power to dispose or to direct the disposition of 820,000 Instruction . For computations regarding securities that represent a right to acquire an underlying security, see

View Full Filing

View this SC 13G filing on SEC EDGAR